Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730698 | 0.81 | CA1 (0.57) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL2782675 | 0.79 | KMT2A (0.56) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL30667581 | 0.79 | KMT2A (0.56) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL15436860 | 0.78 | CA1 (0.50) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL31370732 | 0.77 | HTR2A (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL456018 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL20362789 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL4992955 | 0.77 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL8131 | 0.77 | CA1 (0.58) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28050 | 0.77 | HTR2A (0.58) | CA1CA2HTR2AKMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022269251-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-12-29 | — | — | WO | disclosed |
| EP-3768729-B1 | CONJUGATES OF STANOZOLOL AND HYALURONIC ACID | ACME DRUGS S R L (IT) | 2022-01-26 | — | — | EP | disclosed |
| EP-2256349-B1 | MICRO FLUID DEVICE | SEKISUI CHEMICAL CO LTD (JP) | 2017-04-26 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| EP-3088419-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016120456-A1 | SUPRAMOLECULAR POLYMER BLEND | TECHNISCHE UNIVERSITEIT EINDHOVEN (NL) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016019340-A1 | POLYOXAZOLINE ANTIBODY DRUG CONJUGATES | SERINA THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2015155976-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | 第一三共株式会社 | 2015-10-15 | — | — | WO | disclosed |
| WO-2015146132-A1 | ANTI-CD98 ANTIBODY-DRUG CONJUGATE | 第一三共株式会社 | 2015-10-01 | — | — | WO | disclosed |
| EP-2910573-A1 | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-2907824-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-19 | — | — | EP | disclosed |
| WO-2015098099-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 第一三共株式会社 | 2015-07-02 | — | — | WO | disclosed |
| WO-2015081282-A1 | HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE | REDWOOD BIOSCIENCE, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2014057687-A1 | ANTIBODY-DRUG CONJUGATE | 第一三共株式会社 (JP) | 2014-04-17 | — | — | WO | disclosed |
| EP-2257534-B1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2013-11-06 | — | — | EP | disclosed |
| US-20130052130-A1 | Branched Discreet PEG Constructs | UNIVERSITY OF WASHINGTON (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2258951-A1 | PHOTORESPONSIVE GAS-GENERATING MATERIAL, MICROPUMP AND MICROFLUID DEVICE | Sekisui Chemical Co., Ltd. (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-2256349-A1 | MICRO FLUID DEVICE | Sekisui Chemical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052130-A1 | Branched Discreet PEG Constructs | BTD, DNPEP, IDUA | CA1 1384/4885CA2 3649/4885HTR2A 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.